Sandoz

Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation

21-Aug-2023 By Liza Laws

Novartis’ board of directors has unanimously agreed to separate Sandoz as a 100 per cent spin-off with a $15 billion share buyback.

Generics price fixing charges land pharma firms $447.2m penalty

05-Oct-2021 By Jenni Spinner

The US Department of Justice reports three generic drug manufacturers have been socked with the hefty fine to resolve alleged False Claims Act violations

Sandoz incorporates RFID technology on injectables

20-Oct-2020 By Jenni Spinner

The generic drug manufacturer is working with Kit Check to incorporate the company's drug supply-chain management technology into two of its products.

‘This case is about the color purple’: GSK’s suit against Sandoz refuted

07-Oct-2019 By Ben Hargreaves

England’s High Court throws out the claim that Sandoz’s inhaler product passed off the appearance of GSK’s rival through its use of the color purple in packaging.

Ranitidine recalls sweep globe

26-Sep-2019 By Ben Hargreaves

US, Canadian, South Korean, and Indian authorities recommend the recall of certain ranitidine medicines due to cancer-causing impurity.

Sandoz expands recall to include all lots of ranitidine

24-Sep-2019 By Ben Hargreaves

Sandoz has moved to recall all quantities and lots of ranitidine hydrochloride capsules from the US market due to contamination with NDMA.

Fears over antacid medicine spark ‘industry-wide recalls’

19-Sep-2019 By Ben Hargreaves

Sandoz announces that it will recall its ranitidine medicine, as part of what a spokesperson said were a series of recalls across the industry.

Single dose epinephrine injections from Sandoz to retail at lower cost than generic EpiPens

18-Jul-2019 By Maggie Lynch

Sandoz launches its epinephrine injection Sympjepi for retail across US pharmacies to mitigate the ‘chronic shortages’ of the drug.

Sandoz joins pilot project to develop 2D matrix alternative

18-Jun-2019 By Nick Taylor

Sandoz has signed up to participate in a FDA pilot project to assess the use of RFID as an alternative data carrier to 2D barcodes.

First-of-its-kind approval for Sandoz in China for generic statin

20-May-2019 By Maggie Lynch

Sandoz receives approval of its generic statin in China and states it will continue to grow its generic portfolio in the country.

US generics industry faces antitrust legal backlash over pricing

13-May-2019 By Ben Hargreaves

Teva is at the centre of the allegations made by 44 US states, which suggests a number of companies collaborated to raise prices by as much as 2,000%.

Hired and Retired: Leaving the room

03-May-2019 By Ben Hargreaves

The industry has seen some high profile exits this month, with several individuals vacating, or being asked to vacate, positions on the C-suite.

Hired and Retired: Resignations take industry by surprise

05-Apr-2019 By Ben Hargreaves

March saw significant changes within leadership roles across the industry, with more than one unexpected resignation.

Suboxone competition ramps up as Indivior and Mylan launch generics

25-Feb-2019 By Maggie Lynch

Indivior launches generic of its own Suboxone film in the US, one day after court decision allows rivals to market generic versions.

Sandoz launches EpiPen rival with 16.5% price reduction

21-Jan-2019 By Ben Hargreaves

Sandoz becomes the latest company to launch a generic version of Mylan’s EpiPen in the US and has undercut its rivals on pricing.

Sandoz’ EpiPen rival will launch in Q1, with lower price tag

10-Dec-2018 By Maggie Lynch

Sandoz will launch its epinephrine generic in early 2019 at a lower price point than rival generics on the market.

Casi to create ‘key asset’ manufacturing facility in China

26-Nov-2018 By Ben Hargreaves

The US company will complete a ‘large-scale’ manufacturing facility to support production in the next three to five years.

Novartis recalls NDEA-contaminated tablets in US

12-Nov-2018 By Flora Southey

Sandoz is the latest Zhejiang Huahai Pharmaceutical customer to issue a nationwide recall after trace amounts of a probable carcinogen were found in the supplier’s API.

Olon continues to expand with deal for Indian API facility

11-Sep-2018 By Ben Hargreaves

Olon announced the acquisition of an API manufacturing facility based in Mahad, India.

Novartis sheds oral solid generics in $900m Aurobindo deal

10-Sep-2018 By Flora Southey

In Novartis’ latest restructuring move for 2018, the pharma giant announced plans to sell US generic oral solids and dermatology businesses to Aurobindo Pharma US.

Child opens child-resistant medication, half a million packages recalled

10-Jul-2018 By Ben Hargreaves

Novartis has instigated a voluntary recall of 470,000 packages of drugs, after a child managed to open and swallow a pill from a child-resistant product.